Skip to main content
. Author manuscript; available in PMC: 2021 Mar 15.
Published in final edited form as: Neuropharmacology. 2019 Dec 26;165:107926. doi: 10.1016/j.neuropharm.2019.107926

Fig. 8.

Fig. 8.

Intrathecal administration of 5-HT2C receptor antagonist RS-102221 blocked VPA’s inhibition on visceral hypersensitivity. Intrathecal administration of DMSO (vehicle of RS-102221) and systemic administration of VPA did not change the magnitude of VMR to colorectal distention post FS. 5-HT2C receptor antagonist RS-102221 blocked the anti-hypersensitivity effect of VPA at day 2 post FS, but the effect vanished at day 6 post FS. ** P < 0.01 vs baseline.